ARDELYX, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss
ARDELYX, INC. (ARDX) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-04-30 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-31 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-02 |
| 2023-12-31 | $0.00 10-Q · filed 2024-10-31 |
| 2023-09-30 | $0.00 10-Q · filed 2023-10-31 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |